
Friedrich-Alexander Universität Erlangen-Nürnberg
Articles
-
2 months ago |
academicradiology.org | Friedrich-Alexander Universität Erlangen-Nürnberg |Universitätsklinikum Erlangen
REFERENCES1. Upadhyaya, A. ∙ Upadhyaya, S.A. ∙ Chang, L. ... Ultrasound‑guided percutaneous radiofrequency and microwave ablation for cervical lymph node metastasis from papillary thyroid carcinoma: a systematic review and meta‑analysis of clinical efficacy and safetyAcad Radiol. 2025; S1076-6332(24)01052-3, Epub ahead of print2. Guang, Y. ∙ Luo, Y. ∙ Zhang, Y. ...
-
Oct 30, 2024 |
academic.oup.com | Friedrich-Alexander Universität Erlangen-Nürnberg
The impact of individual biological/targeted synthetic disease-modifying anti-rheumatic drug (b/tsDMARD) on kidney function in patients with rheumatoid arthritis (RA) remains unclear. This study aimed to determine the comparative effects of b/tsDMARDs on chronic kidney disease (CKD) incidence in patients with RA.
-
Jul 22, 2024 |
academic.oup.com | Friedrich-Alexander-University Erlangen-Nürnberg |Universitätsklinikum Erlangen |Deutsches Zentrum Immuntherapie |Friedrich-Alexander Universität Erlangen-Nürnberg
Hypothesizing that early treatment yields improved prognosis, we aimed to investigate how the timing of immunosuppressive treatment relates to interstitial lung disease (ILD) development and the course of pulmonary function in systemic sclerosis (SSc).
-
Feb 15, 2024 |
trialsjournal.biomedcentral.com | Freiburg im Breisgau |Justus-Liebig-University Gießen |Technische Universität Dresden |Friedrich-Alexander Universität Erlangen-Nürnberg
Clinical trials are the most important method for gaining new insights into the connection between medical treatments, environmental influences, and other factors on people’s health. Furthermore, only randomized controlled trials (RCTs) can provide conclusive evidence for causal effectiveness of new drugs and medical procedures on health. As the main link in the chain of evidence, RCTs are crucial for translating scientific results from basic research to clinical application [1, 2].
-
Jan 23, 2024 |
acrjournals.onlinelibrary.wiley.com | Stefan Siebert |Laura Coates |Georg Schett |Friedrich-Alexander Universität Erlangen-Nürnberg
INTRODUCTION Psoriatic arthritis (PsA) is a chronic, heterogeneous, inflammatory disease with multiple musculoskeletal and dermatologic manifestations.1 Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) are typically used as first-line treatments for patients with active peripheral arthritis involvement, while biologic DMARDs (bDMARDs) or targeted synthetic DMARDs are often used for those with an inadequate response to csDMARDs. Although advanced therapies, including...
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →